Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMI6HUW)

• Drug Name: Terbinafine Drug Info
• Synonyms: Bramazil; Lamasil; TerbiFoam; Terbina; Lamisil AT; Lamisil Tablet; Ternbinafine HCl; Lamasil (TN); Lamisil (TN); SF 86-327; Terbisil (TN); Zabel (TN); SF-86-327; Terbinafine (USAN/INN); Terbinafine [USAN:BAN:INN]; Lamisil, Terbinex, Corbinal, Zabel, Terbinafine; Terbinafine, SF-86-327, Lamisil, TBNF; (2E)-N,6,6-trimethyl-N-(1-naphthylmethyl)-2-hepten-4-yn-1-amine; (2E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine; (E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine; (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalene methanamine; (E)-N-(6,6-Dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethylamine; (E)-N-(6,6-dimethyl-2-heptenynyl)-N-methyl-1-naphthalenementhamin hydrochloride
• Therapeutic Class: Antifungal Agents
• Cross-matching ID:
  PubChem CID: 1549008
  ChEBI ID: CHEMBL822
  CAS Number: CAS 91161-71-6
  TTD Drug ID: D01AYJ
  INTEDE Drug ID: DR1557
  ACDINA Drug ID: D00663

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Proteasome	2.45	0.00e+0	44/46 (95.65%)	PSMB3;PSMD11;PSMC1;...
DNA replication	2.30	0.00e+0	34/36 (94.44%)	MCM6;MCM5;RPA3;...
Ribosome biogenesis in eukaryotes	2.24	0.00e+0	52/108 (48.15%)	EIF6;RAN;RPP38;...
Spliceosome	2.14	0.00e+0	101/150 (67.33%)	HSPA8;LSM5;HNRNPM;...
RNA degradation	2.09	0.00e+0	53/79 (67.09%)	LSM5;PFKP;ENO1;...
Homologous recombination	2.06	1.17e-3	35/41 (85.37%)	RPA3;BARD1;BRCA1;...
Oocyte meiosis	1.94	4.01e-3	90/129 (69.77%)	CDC20;MAPK1;PPP3CA;...
Cell cycle	1.93	3.51e-3	110/124 (88.71%)	CDC20;MCM6;MCM5;...
Base excision repair	1.88	8.57e-3	29/33 (87.88%)	POLE2;PARP2;FEN1;...
Mismatch repair	1.85	8.42e-3	22/23 (95.65%)	RPA3;MSH6;MSH2;...
Aminoacyl-tRNA biosynthesis	1.74	2.93e-2	15/66 (22.73%)	IARS2;WARS2;DARS2;...
TNF signaling pathway	-1.70	4.13e-2	103/112 (91.96%)	MMP14;MAP2K7;BIRC2;...
IL-17 signaling pathway	-1.71	3.71e-2	84/94 (89.36%)	MUC5AC;CCL2;DEFB4A;...
Biosynthesis of unsaturated fatty acids	-1.73	3.33e-2	21/27 (77.78%)	HACD3;ACOX3;TECR;...
Lysosome	-1.74	3.19e-2	115/128 (89.84%)	CTSG;LAMP2;AP1G2;...
Mitophagy	-1.78	2.48e-2	56/68 (82.35%)	TAX1BP1;CSNK2B;BCL2L13;...
Epithelial cell signaling in Helicobacter pylori infect...	-1.78	2.71e-2	62/70 (88.57%)	GIT1;HBEGF;CHUK;...
Nicotinate and nicotinamide metabolism	-1.85	1.17e-2	25/35 (71.43%)	NT5C2;SIRT2;NMRK1;...
Histidine metabolism	-1.87	8.64e-3	16/22 (72.73%)	CNDP2;FTCD;ALDH3A1;...
Phenylalanine metabolism	-1.93	8.10e-3	14/17 (82.35%)	ALDH3A1;MAOA;GOT1;...
Viral protein interaction with cytokine and cytokine re...	-2.00	1.85e-3	84/100 (84%)	LTBR;CXCL13;CCL21;...
Sphingolipid metabolism	-2.02	2.16e-3	32/49 (65.31%)	GAL3ST1;SGPL1;KDSR;...
Tryptophan metabolism	-2.06	2.59e-3	35/42 (83.33%)	MAOA;DLD;KYAT1;...
Complement and coagulation cascades	-2.09	3.24e-3	76/85 (89.41%)	CD46;CLU;PLAUR;...
Ferroptosis	-2.12	4.32e-3	36/41 (87.8%)	ACSL4;SLC3A2;PRNP;...
NF-kappa B signaling pathway	-2.15	0.00e+0	90/104 (86.54%)	RELA;CSNK2A2;IRAK4;...
Rheumatoid arthritis	-2.16	0.00e+0	78/93 (83.87%)	HLA-DRA;IL1A;IL15;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H	Hide ▲
MDA-MB-231	CVCL_0062	Homo sapiens	0.01uM - 10uM	24H	Hide ▲

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Liver

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HuH-7	CVCL_0336	Homo sapiens	12uM	72H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H	Show ▼

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.01uM - 10uM	24H	Show ▼

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.04uM - 10uM	24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼
VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Umbilical vein

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HUVEC-C	CVCL_2959	Homo sapiens	0.01uM - 10uM	24H	Show ▼